The investment objective of the Company for the EPR Cell in
respect of the EPR Shares is to provide shareholders with the
opportunity to participate in the performance of shares traded on
various European stock exchanges through the FTSE EPRA Europe Real
Estate Index (the "EPRA Index"). The EPRA Index is an index
designed to track the performance of listed real estate companies
in Europe. The Final Redemption Amount will be determined
principally by reference to two values - the first (defined as the
"Initial Index Level") being the level of the EPRA Index determined
on 13 March 2008, the second (defined as the "Final Index Level")
being the arithmetic average of the levels of the EPRA Index on 13
monthly averaging dates from 13 March 2013 to the Maturity Date
inclusive.
In accordance with the Company's investment objective for the
EPR Cell, the net proceeds at launch were invested into an Index
Derivative Contract (the "EPR Contract") with BNP Paribas, the
Investment Counterparty. Under the terms of the EPR Contract the
Company, on behalf of the EPR Cell, is to receive, at redemption an
amount equalling the funds available for payment of the investment
return.
Full details of the calculation of the investment return, the
EPR Contract and collateral arrangements in favour of the Company
for the account of the EPR Cell are disclosed inthe EPR Cell's
Summary and Securities Note, a copy of which is available from the
Company's Administrator or Distributor upon request.
Energy - Base Metals (3) Cell
The investment objective of the Company for the EBM3 Cell in
respect of the EBM3 Shares is to provide shareholders with a geared
exposure to any increase in the prices of a notional portfolio of
certain energy related and base metal commodities (the "Commodity
Portfolio") over a six-year period. The Commodity Portfolio is a
notional portfolio of commodities comprising 30% crude oil, 20%
aluminium, 20% copper, 15% nickel and 15% zinc.
The investment return of the EBM3 Shares is not subject to the
risk of foreign exchange movements, save to the extent that the
value of the commodities comprised in the notional portfolio, which
are priced in US dollars, may be affected by fluctuations in value
of the US dollar.
In accordance with the Company's investment objective for the
EBM3 Cell, the net proceeds at launch, together with the proceeds
raised in the subsequent issue of further EBM3 Shares, were
invested in an Index Derivative Contract (the "EBM3 Contract") with
BNP Paribas, the Investment Counterparty. Under the terms of the
EBM3 Contract, the Company, on behalf of the EBM3 Cell, is to
receive, at redemption, an amount equalling the funds available for
payment of the investment return.
Full details of the calculation of the investment return, the
EBM3 Contract and collateral arrangements in favour of the Company
for the account of the EBM3 Cell are disclosed inthe EBM3 Cell's
Summary and Securities Note, a copy of which is available from the
Company's Administrator or Distributor upon request.
Enhanced Income Cell
The investment objective of the Company for the EI Cell in
respect of the Class A EIF Shares is to provide shareholders with a
stable stream of quarterly dividend distributions (with a targeted
dividend yield of approximately 8% per annum, subject to increase
and decrease in certain circumstances) and return on capital. Such
investment objective being intended to be achieved by reference to
an investment strategy linked to the total return performance of
the DJES50 Index and notional short-term call options written on
the DJES50 Index.
In accordance with the Company's investment objective for the EI
Cell, the gross proceeds at launch, together with the proceeds
raised in the subsequent issue of further Class A EIF Shares, were
invested into an Index Derivative Contract (the "EI Contract") with
BNP Paribas, the Investment Counterparty.
Under the terms of the EI Contract, the Company, on behalf of
the EI Cell, is to receive an amount initially equal to 2 pence per
Class A EIF Share on each dividend payment date, which will be
applied by the Company in funding the payment of dividends to
shareholders, and, at redemption, an amount equal to the net asset
value of the underlying portfolio.
Full details of the calculation of the investment return, the EI
Contract and the collateral arrangements are disclosed in the EI
Cell's Summary and Securities Note, a copy of which is available
from the Company's Administrator or Distributor upon request.
BNP Paribas COMAC Cell
The investment objective of the Company for the COMAC Cell in
respect of the COMAC Shares is to provide shareholders with
exposure to the performance of an actively managed long short
arbitrage strategy (the "Strategy") based on a portfolio of 25
commodities through the BNP PARIBAS COMAC Long-Short Total Return
Net of Fees Index (the "COMAC Index").
The COMAC Index is denominated in US Dollars and is designed to
track the performance of an actively managed portfolio of 25
commodities selected from the energy, metals and agricultural
sectors, the respective weightings of which are based on an
investment strategy of recommendations provided by the asset
managers which, from time to time, provides the scores used in the
determination of the weightings of the different commodities
comprising the COMAC Index and a rules-based proprietary
methodology designed by BNP Paribas (the "Index Methodology"). The
Strategy is also linked to notional currency hedging intended to
provide a level of protection against fluctuations in the Sterling
/ US Dollar exchange rate.
In accordance with the Company's investment objective for the
COMAC Cell, the net proceeds at launch were invested into an Index
Derivative Contract (the "COMAC Contract") with BNP Paribas, the
Investment Counterparty. Under the terms of the COMAC Contract the
Company, on behalf of the COMAC Cell, is to receive, at redemption,
an amount equalling the funds available for payment of the
investment return.
Full details of the calculation of the investment return, the
COMAC Contract and the collateral arrangements in favour of the
Company, for the account of the COMAC Cell, are disclosed in COMAC
Cell's Summary and Securities Note, a copy of which is available
from the Company's Administrator or Distributor upon request.
In accordance with a Company shareholder written resolution, all
COMAC Shares were redeemed on 2 July 2013.
US Enhanced Income Cell
The investment objective of the Company for the USEI Cell in
respect of the Class A USEI Shares and Class B USEI Shares is to
provide shareholders with a stable stream of quarterly dividend
distributions (with a targeted dividend yield of approximately 8%
per annum, subject to increase and decrease in certain
circumstances) and return on capital. The investment objective is
intended to be achieved by reference to an investment strategy
linked to the total return performance of the Standard and Poor's
500(R)Index (the "S&P500 Index") and notional short-term call
options written on the S&P500 Index.
In accordance with the Company's investment objective for the
USEI Cell, the net proceeds at launch together with the proceeds
raised in the subsequent issue of further Class A USEI Shares and
Class B USEI Shares, were invested into an Index Derivative
Contract (the "USEI Contract") with BNP Paribas, the Investment
Counterparty. Under the terms of the USEI Contract, the Company, on
behalf of the USEI Cell, is to receive an amount initially equal to
2 pence or cents per Class A USEI Share or Class B USEI Share
respectively on each dividend payment date, which will be applied
by the Company in funding the payment of dividends to shareholders,
and, at redemption, an amount equal to the net asset value of the
underlying portfolio.
Full details of the calculation of the investment return, the
USEI Contract and the collateral arrangements in favour of the
Company, for the account of the USEI Cell, are disclosed in the
USEI Cell's Summary and Securities Note, a copy of which is
available from the Company's Administrator or Distributor upon
request.
UK Enhanced Income Cell
The investment objective of the Company for the UKEI Cell in
respect of the UKEI Shares is to provide shareholders with a stable
stream of quarterly dividend distributions (with a targeted
dividend yield of approximately 8% per annum, subject to increase
and decrease in certain circumstances) and return on capital.
The investment objective is intended to be achieved by reference
to an investment strategy linked to the total return performance of
the FTSE 100(TM)Index (the "FTSE100 Index") and notional short-term
call options written on the FTSE100 Index.
In accordance with the Company's investment objective for the
UKEI Cell, the net proceeds raised at launch were invested into an
Index Derivative Contract (the "UKEI Contract") with BNP Paribas,
the Investment Counterparty. Under the terms of the UKEI Contract
the Company, on behalf of the UKEI Cell, is to receive an amount
initially equal to 2 pence per UKEI Share on each dividend payment
date, which will be applied by the Company in funding the payment
of dividends to shareholders, and, at redemption, an amount equal
to the net asset value of the underlying portfolio.
Full details of the calculation of the investment return, the
UKEI Contract and the collateral arrangements in favour of the
Company, for the account of the UKEI Cell, are disclosed in the
UKEI Cell's Summary and Securities Note, a copy of which is
available from the Company's Administrator or Distributor upon
request.
NET ASSET VALUES
Grafico Azioni UK Enhanced In (LSE:UKE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni UK Enhanced In (LSE:UKE)
Storico
Da Mag 2023 a Mag 2024
